North America Breast Cancer Therapeutics Market
Historic Data:    |   Base Year: 2023   |   Forecast Period: 2024-2031
Forecast to 2030 - Regional Analysis - by Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapy), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/ Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), and Distribution Channel (Hospital Pharmacies, Drug Store and Retail Pharmacies, and Online Pharmacies)

No. of Pages: 94    |    Report Code: BMIRE00029747    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
North America Breast Cancer Therapeutics Market

1. Introduction

1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
  • 3.2.1 Hypothesis formulation:
  • 3.2.2 Macro-economic factor analysis:
  • 3.2.3 Developing base number:
  • 3.2.4 Data Triangulation:
  • 3.2.5 Country level data:

4. North America Breast Cancer Therapeutics Market Landscape

4.1 Market Overview
4.2 Porter's Five Forces Analysis
  • 4.2.1 Bargaining Power of Suppliers
  • 4.2.2 Bargaining Power of Buyers
  • 4.2.3 Threat of New Entrants
  • 4.2.4 Competitive Rivalry
  • 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
  • 4.3.1 Raw Material Suppliers
  • 4.3.2 Manufacturers
  • 4.3.3 Distributors/Suppliers
  • 4.3.4 End Users

5. North America Breast Cancer Therapeutics Market – Key Market Dynamics

5.1 Growth Drivers
  • 5.1.1 Growing Burden of Breast Cancers
  • 5.1.2 Launch of Several Diagnostics and Screening Programs
5.2 Market Opportunities
  • 5.2.1 Increased Support From The Government and Private Organizations
5.3 Future Trends
  • 5.3.1 Increasing Use of Personalized Medicine
5.4 Impact of Drivers and Restraints

6. North America Breast Cancer Therapeutics Market Regional Analysis

6.1 North America Breast Cancer Therapeutics Market Overview
6.2 North America Breast Cancer Therapeutics Market Revenue 2020-2030 (US$ Million)
6.3 North America Breast Cancer Therapeutics Market Forecast Analysis

7. North America Breast Cancer Therapeutics Market Analysis – by Drug Therapy

7.1 Targeted Drug Therapy
  • 7.1.1 Overview
  • 7.1.2 Targeted Drug Therapy: North America Breast Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Hormonal Drug Therapy
  • 7.2.1 Overview
  • 7.2.2 Hormonal Drug Therapy: North America Breast Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Chemotherapy
  • 7.3.1 Overview
  • 7.3.2 Chemotherapy: North America Breast Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
7.4 Immunotherapy/Biological Therapy
  • 7.4.1 Overview
  • 7.4.2 Immunotherapy/Biological Therapy: North America Breast Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)

8. North America Breast Cancer Therapeutics Market Analysis – by Breast Cancer Type

8.1 Hormone Receptor
  • 8.1.1 Overview
  • 8.1.2 Hormone Receptor: North America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
8.2 HER2+
  • 8.2.1 Overview
  • 8.2.2 HER2+: North America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
8.3 Triple-Negative Breast Cancer
  • 8.3.1 Overview
  • 8.3.2 Triple-Negative Breast Cancer: North America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)

9. North America Breast Cancer Therapeutics Market Analysis – by Distribution Channel

9.1 Hospital Pharmacies
  • 9.1.1 Overview
  • 9.1.2 Triple-Negative Breast Cancer: North America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
9.2 Drug Store and Retail Pharmacies
  • 9.2.1 Overview
  • 9.2.2 Triple-Negative Breast Cancer: North America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
9.3 Online Pharmacies
  • 9.3.1 Overview
  • 9.3.2 Triple-Negative Breast Cancer: North America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)

10. North America Breast Cancer Therapeutics Market – North America Analysis

10.1 North America
  • 10.1.1 North America Breast Cancer Therapeutics Market Breakdown, by Key Country, 2023 and 2030 (%)
  • 10.1.1.1 North America Breast Cancer Therapeutics Market – Revenue and Forecast Analysis – by Country
  • 10.1.1.1 US: North America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
    • 10.1.1.1.1 US: North America Breast Cancer Therapeutics Market Breakdown, by Drug Therapy
    • 10.1.1.1.2 US: North America Breast Cancer Therapeutics Market Breakdown, by Breast Cancer Type
    • 10.1.1.1.3 US: North America Breast Cancer Therapeutics Market Breakdown, by Distribution Channel
  • 10.1.1.2 Canada: North America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
    • 10.1.1.2.1 Canada: North America Breast Cancer Therapeutics Market Breakdown, by Drug Therapy
    • 10.1.1.2.2 Canada: North America Breast Cancer Therapeutics Market Breakdown, by Breast Cancer Type
    • 10.1.1.2.3 Canada: North America Breast Cancer Therapeutics Market Breakdown, by Distribution Channel
  • 10.1.1.3 Mexico : North America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
    • 10.1.1.3.1 Mexico : North America Breast Cancer Therapeutics Market Breakdown, by Drug Therapy
    • 10.1.1.3.2 Mexico : North America Breast Cancer Therapeutics Market Breakdown, by Breast Cancer Type
    • 10.1.1.3.3 Mexico : North America Breast Cancer Therapeutics Market Breakdown, by Distribution Channel

11. Competitive Landscape

11.1 Heat Map Analysis
11.2 Company Positioning and Concentration

12. North America Breast Cancer Therapeutics Market Industry Landscape

12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 Eli Lilly and Co
  • 13.1.1 Key Facts
  • 13.1.2 Business Description
  • 13.1.3 Products and Services
  • 13.1.4 Financial Overview
  • 13.1.5 SWOT Analysis
  • 13.1.6 Key Developments
13.2 Eisai Co Ltd
  • 13.2.1 Key Facts
  • 13.2.2 Business Description
  • 13.2.3 Products and Services
  • 13.2.4 Financial Overview
  • 13.2.5 SWOT Analysis
  • 13.2.6 Key Developments
13.3 Novartis AG
  • 13.3.1 Key Facts
  • 13.3.2 Business Description
  • 13.3.3 Products and Services
  • 13.3.4 Financial Overview
  • 13.3.5 SWOT Analysis
  • 13.3.6 Key Developments
13.4 AstraZeneca Plc
  • 13.4.1 Key Facts
  • 13.4.2 Business Description
  • 13.4.3 Products and Services
  • 13.4.4 Financial Overview
  • 13.4.5 SWOT Analysis
  • 13.4.6 Key Developments
13.5 Pfizer Inc
  • 13.5.1 Key Facts
  • 13.5.2 Business Description
  • 13.5.3 Products and Services
  • 13.5.4 Financial Overview
  • 13.5.5 SWOT Analysis
  • 13.5.6 Key Developments
13.6 Gilead Sciences Inc
  • 13.6.1 Key Facts
  • 13.6.2 Business Description
  • 13.6.3 Products and Services
  • 13.6.4 Financial Overview
  • 13.6.5 SWOT Analysis
  • 13.6.6 Key Developments
13.7 Merck & Co Inc
  • 13.7.1 Key Facts
  • 13.7.2 Business Description
  • 13.7.3 Products and Services
  • 13.7.4 Financial Overview
  • 13.7.5 SWOT Analysis
  • 13.7.6 Key Developments
13.8 Genentech Inc
  • 13.8.1 Key Facts
  • 13.8.2 Business Description
  • 13.8.3 Products and Services
  • 13.8.4 Financial Overview
  • 13.8.5 SWOT Analysis
  • 13.8.6 Key Developments
13.9 Teva Pharmaceutical Industries Ltd
  • 13.9.1 Key Facts
  • 13.9.2 Business Description
  • 13.9.3 Products and Services
  • 13.9.4 Financial Overview
  • 13.9.5 SWOT Analysis
  • 13.9.6 Key Developments
13.10 Amgen Inc
  • 13.10.1 Key Facts
  • 13.10.2 Business Description
  • 13.10.3 Products and Services
  • 13.10.4 Financial Overview
  • 13.10.5 SWOT Analysis
  • 13.10.6 Key Developments

14. Appendix

14.1 About Business Market Insights

The List of Companies - North America Breast Cancer Therapeutics Market

1. Eli Lilly and Co
2. Eisai Co Ltd
3. Novartis AG
4. AstraZeneca Plc
5. Pfizer Inc
6. Gilead Sciences Inc
7. Merck & Co Inc
8. Genentech Inc
9. Teva Pharmaceutical Industries Ltd
10. Amgen Inc